РЕЗУЛЬТАТИ ВИЗНАЧЕННЯ ХРОНІЧНОЇ ТОКСИЧНОСТІ ТАБЛЕТОК «ДОЛОСАН ФОРТЕ®»
| Autor: | S. I. Trutaev, Yu. B. Laryanovska, S. Yu. Shtrygol |
|---|---|
| Rok vydání: | 2017 |
| Předmět: | |
| Zdroj: | Фармацевтичний часопис. |
| ISSN: | 2414-9926 2312-0967 |
| Popis: | The aim of the study. Evaluation the level of safety of a new combined spasmoanalgetic tablets “Dolosan Forte®” – after chronic administration.Materials and Methods. The tablets “Dolosan Forte®” were worked out by PJSC "Red Star," their composition includes zirilon (2.4-dichlorobenzoic acid potassium salt possessing a signi cant analgesic and anti-in ammatory action), pitofenone hydrochloride (myotropic spasmolytic), and fenpiverinium bromide (M-cholinolytic with additional myotropic and analgesic properties). The chronic toxicity of this drug was studied using the standard protocol presupposing the 30–day course of administration to rats at doses of 2.3 and 23 mg/kg; and rabbits at doses of 1 and 10 mg/kg.Results and Discussion. There was no evidence of intoxication, disturbances of the processes of growth and development, as well as hematological parameters, biochemical parameters of blood and urine, functional state of central nervous system (in the "open eld" test), the kidneys (under the conditions of water diuresis), and myocardium (according to electrocardiogram). According to data obtained in the histological studies, no signs of cardiotoxic, hepatotoxic, and nephrotoxic action of the drug, neither symptoms of the irritating effect on the mucous membranes of the gastrointestinal tract were registered. Also, there was no evidence of the disturbance of the morphofunctional state of the lungs, spleen, thymus, adrenal glands, thyroid gland.Conclusions. The study con rmed the absence of toxic effects of “Dolosan Forte®” after 30-day course of intragastric administration to rats and rabbits at a conventional therapeutic dose and at a conventional increased tenfold therapeutic dose. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|